Juanita Lopez
Overview
Explore the profile of Juanita Lopez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
3479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39846810
Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages and EGFR...
2.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
3.
Chung H, Saada-Bouzid E, Longo F, Yanez E, Im S, Castanon E, et al.
Cancer
. 2024 Jul;
130(19):3278-3288.
PMID: 39031824
Background: Novel treatments are needed for patients with advanced, triple-negative breast cancer (TNBC) that progresses or recurs after first-line treatment with chemotherapy. The authors report results from the TNBC cohort...
4.
Van Zyl M, Barell A, Cooley B, Hanwell J, Parlak J, Banerji U, et al.
Cancer Rep (Hoboken)
. 2024 Jun;
7(6):e2083.
PMID: 38923791
Background: Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials. Aims: We evaluated the use of a geriatric screening tool...
5.
Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, et al.
J Immunother Cancer
. 2024 Jan;
11(11).
PMID: 38243906
Background: ANV419 is a stable antibody-cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its...
6.
Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, et al.
Br J Cancer
. 2023 Jul;
129(5):811-818.
PMID: 37488446
Background: The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates membrane-lipid composition and mitochondrial energy production, inducing cancer cell autophagy. We report...
7.
Mahalingam P, Smith S, Lopez J, Sharma R, Millard T, Thway K, et al.
Rare Tumors
. 2023 Jan;
15:20363613231152333.
PMID: 36698626
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a...
8.
Pettinger C, Livings C, Grochot R, Furness A, Lopez J
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36564127
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and...
9.
Banerjee S, Michalarea V, Ang J, Ingles Garces A, Biondo A, Funingana I, et al.
Clin Cancer Res
. 2022 Aug;
28(21):4634-4641.
PMID: 35984704
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumors. Patients And Methods: A 3+3...
10.
Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35717027
Background: Data suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted a phase 1 dose-escalation trial (NCT02998567) of guadecitabine and pembrolizumab in...